import
tradit
centralis
laboratori
tend
highlight
qualiti
reliabl
test
turnaroundtim
mani
diseas
care
provid
patient
increasingli
expect
patientfocus
specialis
diagnost
test
perform
quickli
easili
provid
result
within
minut
led
develop
easytous
analys
perform
point
care
commonli
known
pointofcar
poc
test
nearpati
test
reason
implement
poct
vari
accord
set
emerg
depart
intens
care
unit
poct
use
find
test
result
immedi
help
guid
lifesav
decis
resourcelimit
set
access
healthcar
facil
typic
limit
set
poct
benefici
term
eas
use
independ
physic
presenc
laboratori
primari
care
set
poct
typic
use
prevent
unnecessari
referr
specialis
secondari
care
guid
diagnost
treatment
decis
provid
reassur
patient
exampl
exclud
ill
rapid
analysi
also
lead
improv
clinic
perform
sinc
elimin
potenti
long
interv
patient
initi
examin
discuss
test
result
first
major
systemat
review
poct
primari
care
publish
year
ago
hobb
et
al
conclud
evid
support
gener
introduct
poct
gener
practic
low
sinc
poc
diagnost
market
grown
substanti
continu
increas
develop
new
support
technolog
novel
biomark
wireless
connect
nanoparticl
techniqu
inform
share
capabl
expect
global
poc
diagnost
market
reach
billion
despit
grow
market
primari
care
clinician
gener
hesit
implement
poct
practic
accord
studi
poc
blood
test
jone
et
al
mainli
concern
accuraci
overreli
test
limit
use
recent
survey
gener
practition
gp
uk
prisma
guidelin
follow
carri
systemat
review
avail
poct
primari
care
sinc
review
aim
identifi
poct
implement
primari
care
type
primari
research
studi
includ
initi
search
reason
requir
specif
outcom
measur
report
initi
search
specif
studi
characterist
picostat
use
part
inclus
criteria
review
protocol
systemat
review
provid
appendix
seri
step
titleabskey
poct
point
care
point
care
test
rapid
test
bedsid
test
laboratoryindepend
near
patient
test
titleabskey
diagno
primari
care
gener
pract
gp
primari
healthcar
primari
health
care
public
met
follow
inclus
criteria
select
review
public
explicitli
state
focu
remot
rural
area
exclud
even
within
develop
countri
public
appli
studi
evalu
poct
term
effect
perform
usag
applic
includ
qualit
studi
survey
interview
model
studi
review
exclud
remov
duplic
public
initi
search
result
abstract
screen
determin
whether
public
met
inclus
criteria
public
undoubtedli
fail
meet
inclus
criteria
base
abstract
screen
exclud
fulltext
assess
doubt
whether
public
met
inclus
criteria
includ
fulltext
assess
abstract
screen
perform
one
review
dl
potenti
issu
discuss
second
review
hk
requir
fulltext
assess
includ
public
perform
one
review
dl
data
extract
manual
one
review
dl
studi
microsoft
excel
version
predefin
label
column
follow
inform
extract
includ
public
studi
design
classifi
accord
one
three
categori
name
empir
studi
trial
cohort
studi
etc
qualit
studi
interview
survey
etc
model
studi
relev
countri
studi
perform
multicountri
studi
individu
countri
count
separ
applic
role
manufactur
play
studi
classifi
one
seven
categori
name
manufactur
provid
financi
support
studi
b
manufactur
fund
studi
c
manufactur
provid
analysertest
manufactur
fund
studi
provid
analysertest
e
one
author
employ
manufactur
f
manufactur
play
part
studi
g
noth
specifi
fund
manufactur
involv
name
poc
devicetest
evalu
biomarkerassay
measur
poct
studi
evalu
one
poct
separ
data
entri
row
ad
individu
test
evalu
fulltext
assess
test
evalu
studi
assess
summaris
extent
predefin
determin
report
determin
identifi
previous
key
factor
affect
decis
implement
poct
primari
care
determin
list
tabl
determin
applic
poct
specif
rather
diseas
preval
gp
practic
frequenc
use
room
innov
risk
exampl
frequenc
use
room
innov
determin
associ
directli
gp
practic
impact
risk
test
would
differ
diseas
expect
determin
report
evalu
frequent
other
uncertainti
first
review
dl
whether
public
discuss
certain
determin
examin
second
review
hk
occas
two
review
could
agre
decis
third
review
involv
make
final
decis
either
rk
mjij
data
extract
includ
public
summaris
text
tabl
format
provid
descript
synthesi
find
result
divid
accord
biomarkerassay
test
measur
total
studi
obtain
initi
search
fulltext
assess
studi
includ
final
review
studi
mostli
exclud
base
fulltext
assess
focu
poc
diagnost
n
instead
describ
tool
strategi
guidelin
support
poc
test
prisma
flow
diagram
search
present
appendix
includ
studi
consist
appli
studi
qualit
studi
simul
studi
studi
use
appli
qualit
method
major
studi
appli
studi
synthesi
set
test
evalu
identifi
percentag
determin
report
test
evalu
provid
figur
togeth
overal
weight
determin
found
four
determin
report
turnaroundtim
n
technic
perform
n
posit
predict
valu
n
neg
predict
valu
n
determin
report
least
evalu
room
innov
n
risk
n
follow
reimburs
n
legisl
n
scientif
evid
n
poct
least
one
test
evalu
frequent
evalu
test
measur
n
crp
n
ddimer
n
influenza
rsv
n
haemoglobin
test
measur
glycat
haemoglobin
give
indic
averag
blood
glucos
level
past
day
see
preval
diabet
continu
rise
year
time
manag
particularli
import
primari
care
pathway
patient
diabet
remain
undiagnos
appendix
b
tabl
list
poct
identifi
review
provid
particular
order
three
evalu
test
dca
vantag
analyz
n
aler
afininion
analyz
n
system
n
ddimer
protein
fragment
produc
blood
clot
dissolv
bodi
high
level
ddimer
therefor
typic
use
assess
risk
thrombot
episod
exclud
condit
deep
vein
thrombosi
pulmonari
embol
appendix
b
tabl
list
ddimer
poct
identifi
review
provid
respiratori
syncyti
viru
rsv
common
viru
caus
lower
respiratori
tract
infect
especi
infant
toddler
sinc
reinfect
occur
throughout
life
specif
fall
winter
gp
emerg
depart
typic
met
surg
patient
visit
colder
month
influenza
commonli
known
flu
also
particularli
preval
children
winter
month
caus
similar
season
overflow
patient
influenza
infecti
diseas
caus
febril
respiratori
ill
typic
remain
undiagnos
sinc
symptom
overlap
significantli
viral
f
g
u
r
e
comparison
determin
weight
accord
gp
percentag
time
determin
report
literatur
bacteri
infect
poc
devic
rsv
influenza
major
posit
impact
patient
care
reduc
unnecessari
diagnost
test
antibiot
prescript
list
poct
influenza
rsv
identifi
review
provid
appendix
b
tabl
addit
abovelist
poct
also
test
measur
calprotectin
streptococcu
pyogen
bnp
ntprobnp
bladder
carcinoma
uric
acid
inr
iga
defici
chlamydia
among
other
major
test
one
evalu
list
test
evalu
provid
appendix
b
tabl
report
aspect
relat
clinic
util
risk
none
none
author
contribut
design
studi
dl
hk
de
